Hikal Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: HIKAL BSE: 524735

₹217.89

Sept. 30, 2026 · NSE · nse_bhavcopy

Peers in Pharmaceuticals & Biotechnology

The largest companies in the same industry by market cap. This company ranks #72 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.

Company	Market cap (₹ Cr)	PE (TTM)	ROE	1Y return	Div. yield	Quality	Valuation	Momentum
Sun Pharmaceutical Industries Limited	435,863	146.5	13.7%	11.0%	—	72	8	30
Divi's Laboratories Limited	246,660	83.9	15.3%	62.7%	0.32%	70	4	51
Torrent Pharmaceuticals Limited	162,454	78.2	12.2%	34.6%	0.79%	56	0	31
Zydus Lifesciences Limited	115,910	33.3	17.3%	17.2%	0.09%	74	24	84
Cipla Limited	108,736	35.4	11.2%	-11.0%	0.97%	73	29	62
Laurus Labs Limited	106,969	122.5	17.1%	127.1%	—	78	24	53
Mankind Pharma Limited	103,406	47.4	11.7%	2.6%	—	68	12	86
Dr. Reddy's Laboratories Limited	102,916	154.7	10.9%	-0.9%	—	62	33	71
Hikal Limited (this stock)	2,687	—	-4.1%	-14.6%	—	38	75	33

Valuation multiples

Current only. Market cap is the whole company's; sales/EBITDA are trailing-twelve-month standalone; debt and cash come from the latest filed standalone balance sheet (March 31, 2026). EBITDA = PBT + interest + depreciation.

Enterprise value

₹3,358 Cr

EV / EBITDA

19.8x

EV / Sales

1.94x

Market cap / Sales

1.55x

Earnings yield

Data unavailable.

Quarterly Financials

Download CSV

Standalone Consolidated

↑ Positive

Quarterly Revenue

Jun 2026 quarterly revenue is Rs 405 Cr, up 6.1% YoY.

Period end	Revenue (₹ Cr)	PBT (₹ Cr)	Net profit (₹ Cr)	Basic EPS
June 30, 2026	403	-10	-8	₹-0.6100
March 31, 2026	519	8	15	₹1.1800
Dec. 31, 2025	494	-9	-6	₹-0.4800
Sept. 30, 2025	318	-47	-35	₹-2.8100
June 30, 2025	380	-31	-23	₹-1.8400
March 31, 2025	552	68	50	₹4.0800
Dec. 31, 2024	448	24	17	₹1.4000
Sept. 30, 2024	453	25	18	₹1.4700
June 30, 2024	407	7	5	₹0.4200
March 31, 2024	514	47	34	₹2.7500
Dec. 31, 2023	448	22	16	₹1.3200
Sept. 30, 2023	435	17	13	₹1.0200
June 30, 2023	388	10	7	₹0.5600

Quarterly income statement (standalone, ₹ Cr)

Indicator	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23
Total income (before exceptional items)	405	526	497	320	381	553	451	453	407	515	448	436	389
Operating revenue	403	519	494	318	380	552	448	453	407	514	448	435	388
Other income	2	7	3	2	1	0	4	0	0	0	0	1	1
Operating expenses	366	414	412	311	356	429	376	378	349	420	383	377	338
Operating profit	37	106	83	7	25	124	72	75	58	94	65	57	50
Operating profit margin	9.2%	20.3%	16.7%	2.3%	6.5%	22.4%	16.1%	16.5%	14.3%	18.4%	14.5%	13.2%	12.9%
Depreciation	43	42	41	41	39	38	33	32	32	32	29	29	28
Interest	15	15	16	15	17	18	19	19	20	15	14	13	14
Exceptional items, gain / (loss)	9	-47	-38	—	—	—	—	—	—	—	—	—	—
Profit before tax	-10	8	-9	-47	-31	68	24	25	7	47	22	17	10
Tax	-2	-6	-3	-12	-8	18	7	6	2	13	5	4	3
Net profit	—	—	—	—	—	50	17	18	5	34	16	13	7
EPS	-0.61	1.18	-0.48	-2.81	-1.84	4.08	1.40	1.47	0.42	2.75	1.32	1.02	0.56
Net profit (TTM)	—	—	—	—	—	91	74	73	68	70	72	82	94
EPS (TTM)	-2.72	-3.95	-1.05	0.83	5.11	7.37	6.04	5.96	5.51	5.65	5.83	6.65	7.64

Total income excludes exceptional items, which are shown on their own row. Trendlyne and Screener fold exceptional items into revenue or other income, so their totals differ from this table by exactly that row.

Annual Financials

Year ended	Revenue (₹ Cr)	PBT (₹ Cr)	Net profit (₹ Cr)
March 31, 2026	1,713	-78	-49
March 31, 2025	1,860	124	91
March 31, 2024	1,785	95	70
March 31, 2023	2,023	105	78

Annual income statement (standalone, ₹ Cr; CAGR to the latest year)

Indicator	CAGR 3Y	CAGR 5Y	Mar 26	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21	Mar 19	Mar 18	Mar 17
Total income (before exceptional items)	-5.3%	0.0%	1,725^†	1,865^†	1,787^†	2,030^†	1,948^†	1,725^†	1,592^†	1,305^†	1,017^†
Operating revenue	-5.4%	0.0%	1,713	1,860	1,785	2,023	1,943^†	1,715^†	1,590^†	1,300^†	1,014^†
Other income	—	—	12^†	5^†	2^†	7^†	5^†	11^†	2^†	4^†	3^†
Operating expenses	—	—	1,492^†	1,531^†	1,518^†	1,768^†	1,602^†	1,398^†	1,291^†	1,058^†	777^†
Operating profit	-4.7%	-7.0%	220^†	328^†	267^†	255^†	341^†	317^†	298^†	242^†	237^†
Operating profit margin	—	—	12.9%^†	17.7%^†	15.0%^†	12.6%^†	17.5%^†	18.5%^†	18.8%^†	18.6%^†	23.4%^†
Depreciation	—	—	164^†	134^†	118^†	109^†	96^†	85^†	93^†	86^†	69^†
Interest	—	—	62^†	75^†	56^†	48^†	31^†	36^†	58^†	49^†	49^†
Exceptional items, gain / (loss)	—	—	-85^†	0^†	0^†	0^†	0^†	0^†	0^†	0^†	0^†
Profit before tax	—	—	-78	124	95	105	219^†	206^†	149^†	112^†	83^†
Tax	—	—	-30^†	33^†	26^†	27^†	58^†	73^†	46^†	34^†	16^†
Net profit	—	—	-49	91	70	78	161^†	133^†	103^†	77^†	67^†
EPS	—	—	-3.95^†	7.37^†	5.65^†	6.35^†	13.02^†	—	—	—	—

^† Derived: the sum of that fiscal year's four quarterly filings (a real annual filing is used wherever one exists). Checked against filed annual figures, the sum lands within 0.5% for about 94% of company-years.

Annual ratios (standalone)

Ratio	Mar 26	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21	Mar 19	Mar 18	Mar 17
Operating margin	12.9%^†	17.7%^†	15.0%^†	12.6%^†	17.5%^†	18.5%^†	18.8%^†	18.6%^†	23.4%^†
EBIT margin	-0.9%^†	10.7%^†	8.5%^†	7.6%^†	12.9%^†	14.1%^†	13.1%^†	12.4%^†	13.0%^†
PBT margin	-4.6%	6.7%	5.3%	5.2%	11.3%^†	12.0%^†	9.4%^†	8.6%^†	8.2%^†
Net margin	-2.8%	4.9%	3.9%	3.9%	8.3%^†	7.8%^†	6.5%^†	5.9%^†	6.6%^†
Interest coverage	-0.26x^†	2.65x^†	2.69x^†	3.19x^†	8.00x^†	6.70x^†	3.55x^†	3.27x^†	2.70x^†
Dividend payout	—	—	—	—	—	—	—	—	—
Earnings retention	—	—	—	—	—	—	—	—	—
Current ratio	1.30x	1.26x	—	—	—	—	—	—	—
Quick ratio	0.78x	0.84x	—	—	—	—	—	—	—
Debt to equity	0.57x	0.60x	—	—	—	—	—	—	—
Return on equity	-4.1%	7.2%	—	—	—	—	—	—	—
Return on assets	-2.1%	3.6%	—	—	—	—	—	—	—
Return on capital employed	-1.0%^†	11.4%^†	—	—	—	—	—	—	—
Asset turnover	0.72x	0.74x	—	—	—	—	—	—	—

Margins and asset turnover use operating revenue (interest earned for banks, excluding other income), not total income. Liquidity, leverage and return ratios need a filed standalone balance sheet, which exists only for recent years; returns use year-end equity/assets. Dividend payout is shown only for companies with a dividend record. † = built from a summed fiscal year.

Revenue Mix

Data unavailable.

Cash Flow

Year ended	Operating (₹ Cr)	Investing (₹ Cr)	Financing (₹ Cr)	Capex (₹ Cr)	Free Cash Flow (₹ Cr)
March 31, 2026	302	-145	-160	148	154
March 31, 2025	280	-136	-144	137	143
March 31, 2024	187	-174	-27	204	-18
March 31, 2023	315	-292	-8	303	13

Balance Sheet (standalone)

Year ended	Total Assets (₹ Cr)	Total Equity (₹ Cr)	Reserves (₹ Cr)	Borrowings, Current (₹ Cr)	Borrowings, Non-current (₹ Cr)	Current Assets (₹ Cr)	Current Liabilities (₹ Cr)	Cash & Equivalents (₹ Cr)	Net Block (₹ Cr)	Inventory (₹ Cr)
March 31, 2026	2,365	1,199	1,174	308	373	884	679	10	1,327	358
March 31, 2025	2,529	1,262	1,238	395	367	997	790	13	1,357	334
March 31, 2024	—	—	—	—	—	—	—	—	—	—
March 31, 2023	—	—	—	—	—	—	—	—	—	—

Financial charts

Trend charts drawn from the standalone income-statement and ratio tables above (oldest year on the left); a gap means that period has no figure. Annual years marked † in the tables are derived from four quarters.